Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 2, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Fiyinfolu O Balogun1,2,3, Mara H Sherman2,4, Wungki Park1,2,3

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Cancer Discovery
|July 1, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials.

JCO oncology practice·2026
Same author

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same author

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Hierarchical classification of immune cell transcriptomes at population-scale.

bioRxiv : the preprint server for biology·2026
Same author

Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report.

Journal of gastrointestinal oncology·2026
Same author

Pancreatic cancer.

Nature reviews. Disease primers·2026

Pancreatic ductal adenocarcinoma (PDAC) is a challenging cancer with poor outcomes. Emerging targeted and immunomodulatory therapies show promise for improving treatment paradigms and patient survival.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) represents 90% of pancreatic cancers, characterized by a poor prognosis.
  • Resectability at diagnosis is low (10-15%), with a small percentage (5-15%) amenable to surgery after therapy.
  • Chemotherapy is standard, and targeted therapies are expanding for specific genomic alterations.

Purpose of the Study:

  • To review the current management of PDAC.
  • To focus on emerging treatment paradigms, including targeted and immunomodulatory agents.

Main Methods:

  • Review of current literature on PDAC management.
  • Analysis of emerging targeted and immunomodulatory therapies.
  • Discussion of the role of the tumor microenvironment.

More Related Videos

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Related Experiment Videos

Last Updated: Jul 2, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Main Results:

  • PDAC exhibits unique genomic, immunologic, and clinical features.
  • The tumor microenvironment contributes to treatment resistance.
  • New targeted and immunomodulatory therapies are being developed.

Conclusions:

  • Advances in understanding PDAC pathobiology are leading to novel therapies.
  • Targeted and immunomodulatory agents are expected to alter treatment paradigms.
  • These advancements hold potential for improving outcomes in this difficult-to-treat malignancy.